Inclusion and Exclusion Criteria
This review is inclusive of all research articles presenting original
data that reported infectious complications of mTOR inhibitors
(sirolimus/rapamycin or everolimus) in the treatment of VAs. We did not
restrict inclusion based on the year of publication. For inclusion,
patients reported in the study had to have (1) been diagnosed with a VA,
(2) received sirolimus or everolimus, and (3) had a reported infectious
complication. Exclusion criteria included articles that (1) did not
report original data (e.g. review articles and commentaries), (2) did
not report infections, (3) were not available in English, or (4) were
abstracts, trial protocols, or dissertations. We included studies of
both children and adults with VAs.